Susan Burgin, D.T.M.&H., M.B.,B.Ch.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatology | 29 | 2022 | 920 | 7.880 |
Why?
|
| Teaching | 14 | 2019 | 1174 | 4.350 |
Why?
|
| Learning | 12 | 2020 | 1762 | 2.510 |
Why?
|
| Teaching Rounds | 3 | 2016 | 280 | 1.120 |
Why?
|
| Drug Eruptions | 4 | 2021 | 335 | 1.080 |
Why?
|
| Skin Diseases | 6 | 2017 | 1099 | 1.070 |
Why?
|
| Skin | 9 | 2021 | 4520 | 1.010 |
Why?
|
| Education, Medical | 4 | 2018 | 1742 | 0.840 |
Why?
|
| Exanthema | 4 | 2017 | 504 | 0.820 |
Why?
|
| Problem-Based Learning | 4 | 2018 | 356 | 0.810 |
Why?
|
| Educational Measurement | 2 | 2018 | 1256 | 0.730 |
Why?
|
| Dermatitis, Contact | 1 | 2021 | 133 | 0.710 |
Why?
|
| Education, Medical, Continuing | 2 | 2016 | 829 | 0.690 |
Why?
|
| Psychological Theory | 2 | 2018 | 176 | 0.680 |
Why?
|
| Art | 1 | 2020 | 64 | 0.650 |
Why?
|
| Faculty, Medical | 2 | 2017 | 1218 | 0.630 |
Why?
|
| Vulva | 1 | 2018 | 84 | 0.620 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2018 | 1081 | 0.620 |
Why?
|
| Models, Educational | 2 | 2018 | 375 | 0.610 |
Why?
|
| Eczema | 1 | 2021 | 246 | 0.610 |
Why?
|
| Preceptorship | 1 | 2018 | 56 | 0.600 |
Why?
|
| Graft vs Host Reaction | 1 | 2017 | 99 | 0.590 |
Why?
|
| Acyclovir | 2 | 2016 | 267 | 0.580 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2017 | 44 | 0.570 |
Why?
|
| Internship and Residency | 7 | 2019 | 5952 | 0.570 |
Why?
|
| Folliculitis | 1 | 2016 | 25 | 0.520 |
Why?
|
| Vulvar Neoplasms | 1 | 2018 | 267 | 0.520 |
Why?
|
| Mohs Surgery | 1 | 2018 | 222 | 0.520 |
Why?
|
| Fibroma | 1 | 2017 | 201 | 0.510 |
Why?
|
| Calciphylaxis | 1 | 2017 | 130 | 0.490 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2014 | 23 | 0.480 |
Why?
|
| Herpesvirus 3, Human | 1 | 2016 | 159 | 0.480 |
Why?
|
| Malignant Atrophic Papulosis | 1 | 2014 | 7 | 0.470 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2015 | 75 | 0.470 |
Why?
|
| Education | 1 | 2017 | 536 | 0.460 |
Why?
|
| Valine | 1 | 2016 | 410 | 0.450 |
Why?
|
| Foot Diseases | 1 | 2015 | 148 | 0.450 |
Why?
|
| Bronchiectasis | 1 | 2015 | 139 | 0.440 |
Why?
|
| Onycholysis | 1 | 2013 | 3 | 0.440 |
Why?
|
| Hospitals, Teaching | 1 | 2018 | 1158 | 0.440 |
Why?
|
| Epidermolysis Bullosa Acquisita | 1 | 2013 | 16 | 0.430 |
Why?
|
| Motivation | 3 | 2018 | 2034 | 0.430 |
Why?
|
| Herpes Zoster | 1 | 2016 | 253 | 0.430 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2018 | 564 | 0.430 |
Why?
|
| Peer Group | 1 | 2018 | 697 | 0.420 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 937 | 0.410 |
Why?
|
| Sarcoma, Kaposi | 1 | 2015 | 374 | 0.400 |
Why?
|
| Culture | 1 | 2016 | 624 | 0.390 |
Why?
|
| Ambulatory Care Facilities | 1 | 2018 | 941 | 0.390 |
Why?
|
| Workload | 1 | 2017 | 852 | 0.380 |
Why?
|
| Skin Neoplasms | 3 | 2018 | 5891 | 0.380 |
Why?
|
| Dermatomyositis | 1 | 2014 | 266 | 0.360 |
Why?
|
| Pemphigus | 1 | 2012 | 108 | 0.360 |
Why?
|
| Physical Examination | 1 | 2016 | 1262 | 0.350 |
Why?
|
| Ambulatory Care | 2 | 2018 | 2780 | 0.350 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 1514 | 0.350 |
Why?
|
| Chromoblastomycosis | 1 | 2009 | 1 | 0.340 |
Why?
|
| Buttocks | 1 | 2009 | 112 | 0.320 |
Why?
|
| Patients | 1 | 2015 | 909 | 0.320 |
Why?
|
| Ascomycota | 1 | 2009 | 81 | 0.320 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 2411 | 0.310 |
Why?
|
| Students | 2 | 2022 | 1751 | 0.310 |
Why?
|
| Herpes Simplex | 1 | 2012 | 470 | 0.310 |
Why?
|
| Humans | 58 | 2022 | 768451 | 0.300 |
Why?
|
| Attitude to Health | 1 | 2016 | 2030 | 0.290 |
Why?
|
| Clinical Competence | 2 | 2019 | 4841 | 0.270 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 1950 | 0.270 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2016 | 1176 | 0.270 |
Why?
|
| Emotions | 1 | 2018 | 2773 | 0.260 |
Why?
|
| Granuloma Annulare | 1 | 2005 | 29 | 0.250 |
Why?
|
| Referral and Consultation | 1 | 2018 | 3629 | 0.250 |
Why?
|
| Rickettsiaceae Infections | 1 | 2004 | 2 | 0.250 |
Why?
|
| Cytomegalovirus Infections | 1 | 2012 | 839 | 0.240 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2017 | 4534 | 0.240 |
Why?
|
| Mucous Membrane | 1 | 2008 | 660 | 0.240 |
Why?
|
| Telemedicine | 1 | 2021 | 3104 | 0.230 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 3484 | 0.230 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2003 | 42 | 0.220 |
Why?
|
| Quality Improvement | 1 | 2018 | 3858 | 0.210 |
Why?
|
| History, 19th Century | 2 | 2015 | 716 | 0.210 |
Why?
|
| Adenoma, Sweat Gland | 1 | 2002 | 17 | 0.200 |
Why?
|
| Eccrine Glands | 1 | 2002 | 52 | 0.200 |
Why?
|
| History, 21st Century | 2 | 2020 | 1575 | 0.190 |
Why?
|
| Water Loss, Insensible | 1 | 2021 | 12 | 0.190 |
Why?
|
| Emollients | 1 | 2021 | 42 | 0.180 |
Why?
|
| Erythema | 2 | 2017 | 262 | 0.180 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2002 | 116 | 0.180 |
Why?
|
| Histamine Antagonists | 1 | 2021 | 93 | 0.180 |
Why?
|
| Students, Medical | 3 | 2018 | 1962 | 0.180 |
Why?
|
| History, 20th Century | 2 | 2020 | 2772 | 0.170 |
Why?
|
| Crohn Disease | 1 | 2013 | 2293 | 0.170 |
Why?
|
| Antiviral Agents | 3 | 2021 | 3063 | 0.170 |
Why?
|
| Humanities | 1 | 2020 | 55 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 5709 | 0.160 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 4984 | 0.160 |
Why?
|
| Administration, Cutaneous | 1 | 2021 | 716 | 0.160 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2002 | 595 | 0.150 |
Why?
|
| Antigens, CD | 1 | 2008 | 4029 | 0.150 |
Why?
|
| Internet | 2 | 2021 | 3123 | 0.140 |
Why?
|
| Thiosulfates | 1 | 2017 | 53 | 0.140 |
Why?
|
| Observation | 1 | 2018 | 311 | 0.140 |
Why?
|
| Group Processes | 1 | 2018 | 228 | 0.140 |
Why?
|
| Thinking | 1 | 2020 | 320 | 0.140 |
Why?
|
| Urban Population | 1 | 2004 | 2047 | 0.130 |
Why?
|
| Angiomatosis, Bacillary | 1 | 1996 | 4 | 0.130 |
Why?
|
| Leg Ulcer | 1 | 2016 | 71 | 0.130 |
Why?
|
| Chelating Agents | 1 | 2017 | 385 | 0.130 |
Why?
|
| Biopsy | 2 | 2018 | 6816 | 0.120 |
Why?
|
| Personal Autonomy | 1 | 2018 | 315 | 0.120 |
Why?
|
| Videoconferencing | 1 | 2017 | 207 | 0.120 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2016 | 86 | 0.120 |
Why?
|
| Feedback | 1 | 2018 | 794 | 0.120 |
Why?
|
| Physician Executives | 1 | 2015 | 137 | 0.120 |
Why?
|
| Thigh | 1 | 2016 | 239 | 0.120 |
Why?
|
| History, 18th Century | 1 | 2015 | 207 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 9263 | 0.120 |
Why?
|
| Stomach Ulcer | 1 | 2014 | 122 | 0.110 |
Why?
|
| Sweating | 1 | 2014 | 155 | 0.110 |
Why?
|
| Histiocytosis | 1 | 2013 | 39 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 13026 | 0.110 |
Why?
|
| Self Efficacy | 1 | 2018 | 651 | 0.110 |
Why?
|
| Esophageal Diseases | 1 | 2014 | 168 | 0.110 |
Why?
|
| Educational Status | 1 | 2020 | 2519 | 0.110 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2015 | 289 | 0.100 |
Why?
|
| Ulcer | 1 | 2014 | 204 | 0.100 |
Why?
|
| Comprehension | 1 | 2018 | 641 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2021 | 4041 | 0.100 |
Why?
|
| Patient Participation | 1 | 2021 | 1450 | 0.100 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 2126 | 0.100 |
Why?
|
| Male | 17 | 2018 | 364781 | 0.100 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1996 | 664 | 0.100 |
Why?
|
| Lymphatic Diseases | 1 | 2013 | 320 | 0.100 |
Why?
|
| Awareness | 1 | 2016 | 654 | 0.100 |
Why?
|
| Biological Products | 1 | 2021 | 937 | 0.090 |
Why?
|
| Glucocorticoids | 1 | 2021 | 2170 | 0.090 |
Why?
|
| Ganciclovir | 1 | 2012 | 256 | 0.090 |
Why?
|
| Muscle Weakness | 1 | 2014 | 415 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2019 | 2508 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 1320 | 0.090 |
Why?
|
| Prednisolone | 1 | 2012 | 327 | 0.090 |
Why?
|
| Attitude | 1 | 2015 | 773 | 0.090 |
Why?
|
| Purpura | 1 | 2011 | 117 | 0.090 |
Why?
|
| Adult | 13 | 2016 | 223542 | 0.090 |
Why?
|
| Arthralgia | 1 | 2014 | 462 | 0.090 |
Why?
|
| Female | 16 | 2018 | 396943 | 0.090 |
Why?
|
| Measles | 1 | 2012 | 181 | 0.090 |
Why?
|
| Fever | 1 | 2017 | 1622 | 0.090 |
Why?
|
| Melanoma | 1 | 2008 | 5740 | 0.080 |
Why?
|
| Itraconazole | 1 | 2009 | 43 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2014 | 1840 | 0.080 |
Why?
|
| Dermatitis | 1 | 2011 | 203 | 0.080 |
Why?
|
| Perception | 1 | 2015 | 1207 | 0.080 |
Why?
|
| Antioxidants | 1 | 2017 | 1678 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 8559 | 0.080 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 1134 | 0.080 |
Why?
|
| Cryotherapy | 1 | 2009 | 160 | 0.080 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 1282 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2020 | 3955 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 20762 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2021 | 65409 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2014 | 1218 | 0.070 |
Why?
|
| Nail Diseases | 1 | 2008 | 55 | 0.070 |
Why?
|
| Platinum Compounds | 1 | 2008 | 95 | 0.070 |
Why?
|
| Lung | 2 | 2017 | 10090 | 0.070 |
Why?
|
| Antimetabolites | 1 | 2008 | 129 | 0.070 |
Why?
|
| Hair Diseases | 1 | 2008 | 72 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2008 | 13708 | 0.070 |
Why?
|
| Blister | 1 | 2007 | 88 | 0.070 |
Why?
|
| Tattooing | 1 | 2007 | 57 | 0.070 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 166 | 0.070 |
Why?
|
| Eosinophils | 1 | 2012 | 955 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 2819 | 0.070 |
Why?
|
| Shoulder Joint | 1 | 2013 | 749 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2019 | 8730 | 0.070 |
Why?
|
| Curriculum | 1 | 2020 | 3778 | 0.070 |
Why?
|
| Middle Aged | 11 | 2017 | 223418 | 0.070 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2008 | 430 | 0.060 |
Why?
|
| Niacinamide | 1 | 2008 | 419 | 0.060 |
Why?
|
| Osteoarthritis | 1 | 2013 | 1070 | 0.060 |
Why?
|
| Aged | 5 | 2017 | 171520 | 0.060 |
Why?
|
| Phenylurea Compounds | 1 | 2008 | 532 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 59680 | 0.060 |
Why?
|
| Taxoids | 1 | 2008 | 669 | 0.060 |
Why?
|
| Antibodies, Viral | 1 | 2016 | 3212 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2009 | 761 | 0.060 |
Why?
|
| China | 1 | 2009 | 2398 | 0.050 |
Why?
|
| Doxycycline | 1 | 2004 | 348 | 0.050 |
Why?
|
| Benzamides | 1 | 2008 | 1381 | 0.050 |
Why?
|
| New York City | 1 | 2004 | 738 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 1816 | 0.050 |
Why?
|
| Pyrroles | 1 | 2008 | 1127 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 3922 | 0.050 |
Why?
|
| Pandemics | 1 | 2021 | 8753 | 0.050 |
Why?
|
| Quinazolines | 1 | 2008 | 1376 | 0.050 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2016 | 2444 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2008 | 1044 | 0.040 |
Why?
|
| United States | 3 | 2022 | 73121 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 9425 | 0.040 |
Why?
|
| Cognition | 1 | 2017 | 7066 | 0.040 |
Why?
|
| Indoles | 1 | 2008 | 1834 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 5192 | 0.040 |
Why?
|
| Faculty | 1 | 2022 | 384 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 2434 | 0.040 |
Why?
|
| South Africa | 4 | 1996 | 1870 | 0.040 |
Why?
|
| Piperazines | 1 | 2008 | 2546 | 0.040 |
Why?
|
| Autoantibodies | 2 | 1996 | 2131 | 0.040 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 1996 | 62 | 0.030 |
Why?
|
| Pyridines | 1 | 2008 | 2888 | 0.030 |
Why?
|
| Erythromycin | 1 | 1996 | 115 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2008 | 3050 | 0.030 |
Why?
|
| Schools, Medical | 1 | 2022 | 881 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2005 | 1794 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 2279 | 0.030 |
Why?
|
| Anticonvulsants | 1 | 2005 | 1923 | 0.030 |
Why?
|
| Antibodies, Antinuclear | 1 | 1996 | 343 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 26351 | 0.030 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2005 | 1644 | 0.030 |
Why?
|
| Quality of Life | 1 | 2015 | 13497 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 1996 | 360 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 1996 | 2173 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 4362 | 0.030 |
Why?
|
| Community-Acquired Infections | 1 | 1996 | 473 | 0.020 |
Why?
|
| Autoantigens | 1 | 1996 | 894 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 5709 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 60045 | 0.020 |
Why?
|
| Jews | 1 | 2011 | 358 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2005 | 4840 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2008 | 23638 | 0.010 |
Why?
|
| Pneumonia | 1 | 1996 | 2162 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1996 | 4572 | 0.010 |
Why?
|
| Lasers | 1 | 2007 | 952 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1996 | 7471 | 0.010 |
Why?
|
| HIV Infections | 1 | 2003 | 17564 | 0.010 |
Why?
|
| Counterimmunoelectrophoresis | 1 | 1996 | 14 | 0.010 |
Why?
|
| IgG Deficiency | 1 | 1996 | 28 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 15965 | 0.010 |
Why?
|
| Raynaud Disease | 1 | 1996 | 79 | 0.010 |
Why?
|
| Vasculitis | 1 | 1996 | 524 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1996 | 1393 | 0.010 |
Why?
|
| Acute Disease | 1 | 1996 | 7246 | 0.000 |
Why?
|
| Kidney Diseases | 1 | 1996 | 2102 | 0.000 |
Why?
|
| Adolescent | 3 | 1996 | 89168 | 0.000 |
Why?
|
| Psychotic Disorders | 1 | 1996 | 3278 | 0.000 |
Why?
|
| Prevalence | 1 | 1996 | 15880 | 0.000 |
Why?
|
| Retrospective Studies | 2 | 1996 | 81834 | 0.000 |
Why?
|
| Prognosis | 1 | 1996 | 30028 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1996 | 54914 | 0.000 |
Why?
|